JP2021513963A5 - - Google Patents

Info

Publication number
JP2021513963A5
JP2021513963A5 JP2020543209A JP2020543209A JP2021513963A5 JP 2021513963 A5 JP2021513963 A5 JP 2021513963A5 JP 2020543209 A JP2020543209 A JP 2020543209A JP 2020543209 A JP2020543209 A JP 2020543209A JP 2021513963 A5 JP2021513963 A5 JP 2021513963A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
haloalkyl
formula
compound according
Prior art date
Application number
JP2020543209A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019161345A5 (https=
JP2021513963A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018441 external-priority patent/WO2019161345A1/en
Publication of JP2021513963A publication Critical patent/JP2021513963A/ja
Publication of JPWO2019161345A5 publication Critical patent/JPWO2019161345A5/ja
Publication of JP2021513963A5 publication Critical patent/JP2021513963A5/ja
Pending legal-status Critical Current

Links

JP2020543209A 2018-02-19 2019-02-18 異常増殖性疾患を治療するための薬剤および方法 Pending JP2021513963A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632372P 2018-02-19 2018-02-19
US62/632,372 2018-02-19
PCT/US2019/018441 WO2019161345A1 (en) 2018-02-19 2019-02-18 Agents and methods for treating dysproliferative diseases

Publications (3)

Publication Number Publication Date
JP2021513963A JP2021513963A (ja) 2021-06-03
JPWO2019161345A5 JPWO2019161345A5 (https=) 2022-03-01
JP2021513963A5 true JP2021513963A5 (https=) 2022-03-01

Family

ID=67619605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543209A Pending JP2021513963A (ja) 2018-02-19 2019-02-18 異常増殖性疾患を治療するための薬剤および方法

Country Status (9)

Country Link
US (2) US12215090B2 (https=)
EP (1) EP3755693B1 (https=)
JP (1) JP2021513963A (https=)
KR (1) KR20200123184A (https=)
CN (1) CN112351977A (https=)
AU (1) AU2019221837B2 (https=)
CA (1) CA3091642A1 (https=)
IL (1) IL276639A (https=)
WO (1) WO2019161345A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113149942B (zh) * 2021-02-10 2023-06-02 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种洛克米兰醇酚羟基衍生物、其制备方法和应用
WO2022221519A1 (en) * 2021-04-14 2022-10-20 Memorial Sloan-Kettering Cancer Center Synthetic rocaglates with broad-spectrum antiviral activities and uses thereof
CN121712777A (zh) * 2023-08-18 2026-03-20 皇家学术促进机构麦吉尔大学 Rna解旋酶抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19934952A1 (de) * 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
AUPQ866500A0 (en) 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
US7816544B2 (en) 2004-03-23 2010-10-19 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
CA2652873A1 (en) 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
EP2189158A1 (en) 2008-11-20 2010-05-26 DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
EP2189453A1 (en) 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
WO2011140334A2 (en) * 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
US20140255432A1 (en) 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2013170257A1 (en) 2012-05-11 2013-11-14 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
WO2015085221A2 (en) 2013-12-05 2015-06-11 Memorial Sloan Kettering Cancer Center Methods for identifying anti-cancer compounds
JP6306481B2 (ja) 2014-03-17 2018-04-04 株式会社神戸製鋼所 延性及び曲げ性に優れた高強度冷延鋼板および高強度溶融亜鉛めっき鋼板、並びにそれらの製造方法
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
EP3888658B1 (en) * 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
US10639378B2 (en) * 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use

Similar Documents

Publication Publication Date Title
JP2021513963A5 (https=)
JP2019512478A5 (https=)
JP2016503414A5 (https=)
JP2018516243A5 (https=)
JP2021532162A5 (https=)
CA2750413A1 (en) Hydroxamic acid derivatives
JP2020525429A5 (https=)
JP2021514400A5 (https=)
JP2017536344A5 (https=)
RU2013156074A (ru) Диазакарбазолы и способы применения
JP2018511628A5 (https=)
HRP20211297T1 (hr) Aril- ili heteroaril-supstituirani benzenovi spojevi
JP2018528261A5 (https=)
JP2016519062A5 (https=)
JP2006515858A5 (https=)
JP2018511590A5 (https=)
JP2021514395A5 (https=)
AR067896A1 (es) Procedimiento para sintetizar compuestos utiles para tratar hepatitis c
JP2013544846A5 (https=)
JP2018502902A5 (https=)
TR201809990T4 (en) NEW COMPOSITIONS, USES AND METHODS FOR THEIR MAKING.
JP2016507575A5 (https=)
HRP20200907T1 (hr) Inhibitor alkinil piridin prolil hidroksilaze, metoda pripreme i njegova medicinska primjena
NZ731966A (en) Novel imaging composition and uses thereof
JP2006509842A5 (https=)